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Tuesday, February 5, 2013 445aRyR1 and its protein ligands are often not stable in vitro and therefore difficult
to study by single-particle cryo-electron microscopy (cryo-EM). The main goal
of this study was to develop a procedure to cross-link protein ligands to RyR1
and visualize these complexes by single-particle cryo-EM. To test the cross-
linking protocol we used the complex of FK506-binding protein and RyR1
(FKBP12:RyR1) as a model system, since the structure of FKBP12:RyR1 is
known. Glutaraldehyde quantitatively cross-linked RyR1 subunits to each other
and FKBP12 to RyR1 without damaging the ultrastructure. Cross-linked
FKBP12:RyR1 was visualized in 2D averages, and was identical to that of pre-
viously published non-cross-linked FKBP12:RyR1. The effect of glutaralde-
hyde cross-linking on RyR1 structure was characterized using 3D single-
particle cryo-EM and by [3H]ryanodine binding assay. Glutaraldehyde cross-
linking preserved the gross morphology of RyR1, but induced minor structural
changes at the cytoplasmic and transmembrane regions of RyR1. Glutaralde-
hyde cross-linking enhanced [3H]ryanodine binding to RyR1 by ~30%. Based
on these results we propose that cross-linking RyR1 subunits by glutaraldehyde
locked RyR1 in an open-like conformation state.
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The type 1 ryanodine receptor (RyR1) is an intracellular Ca2þ release channel
that mediates skeletal muscle excitation contraction coupling. While the over-
all shape of RyR1 has been elucidated using cryo electron microscopic recon-
structions, fine structural details remain elusive. To better understand the
structure of RyR1, we have previously used a fluorescence resonance energy
transfer (FRET)-based method using a fused green fluorescent protein (GFP)
donor and a fluorescent acceptor, Cy3NTA that binds specifically to short
poly-histidine ‘tags’ engineered into RyR1. However, the large size of the
GFP fusions and the need to permeabilize cells expressing these constructs
(to allow Cy3NTA entry) limits interpretation of the resulting FRET data.
To overcome these problems, we used a dodecapeptide sequence containing
a tetracysteine (Tc) motif to target the bi-arsenical fluorophores, FlAsH and
ReAsH to RyR1. These compounds freely cross intact cell membranes where
they then bind covalently to the tetracysteine motif. First, we used this system
to conduct FRET measurements in intact cells by fusing a YFP FRET donor
to the N-terminus of RyR1 and then targeting the FRET acceptor, ReAsH to
an adjacent Tc tag. High levels of energy transfer (~50%) were observed
whereas incubation of ReAsH with a YFP-RyR1 fusion protein lacking the
Tc tag resulted in no detectable FRET. We also developed a FRET-based
system that did not require GFP fusions into RyR1 by labeling N-terminal
Tc-tagged RyR1 with FlAsH, a FRET donor and then targeting the FRET
acceptor Cy3NTA to an adjacent His tag. A high degree of energy transfer
(~70%) indicated proper binding of both compounds to these unique recogni-
tion sequences in RyR1. Thus, these two systems provide unprecedented flex-
ibility in FRET-based structural determinations of RyR1. Supported by NIH
grant R01AR059124.
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We used fluorescence resonance energy transfer (FRET) to localize three
divergent region domains within the type 1 ryanodine receptor (RyR1), an in-
tracellular Ca2þ channel that mediates skeletal muscle excitation-contraction
(EC) coupling. Initial cloning studies of the three RyR isoforms identified
three ‘‘divergent regions’’ of primary sequence dissimilarity spanning amino
acids 4254-4631 (DR1), 1342-1403 (DR2) and 1872-1923 (DR3) in RyR1.
These regions have been implicated in EC coupling as well as in differential
sensitivity to pharmacological agonists. Here, we used permeabilized HEK-
293T cells expressing recombinant RyR1 to localize these DRs to the cryo
electron microscopic (EM) map of RyR1. First, we measured FRET from
a green fluorescent protein (GFP) donor fused to either position 1 or 620 of
RyR1, to a FRET acceptor, Cy3NTA, targeted to poly-histidine ‘‘tags’’ in-
serted into DR1 (at position 4429), DR2 (at position1358) or DR3 (at position
1915). While FRET was not detected for His-tagged constructs containing
GFP fused at position 1, FRET was observed from GFP fused at position
620 to all 3 His-tagged positions. Second, we targeted a donor to the RyR1
cytoplasmic domain using FKBP12.6 labeled with Alexa Fluor 488, and
then measured FRET to Cy3NTA targeted to the His tag sites describedabove. Donor-FKBPs bound with high-affinity to both recombinant wild
type and His-tagged RyRs. FRET was detected from donor conjugated to
each of four, well-separated positions on FKBP to Cy3NTA targeted to
each divergent region. Since the fused GFPs and FKBP12.6 have already
been localized within the cryo EM map of RyR1, we can now triangulate
the DR positions to the cryo EM map from these two complementary data
sets. Supported by NIH grant R01AR059124 (to JDF, MM, and TG) and
R01HL092097 (to RLC).
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The skeletal muscle Ryanodine Receptor (RyR1) is a large calcium release
channel involved in excitation-contraction coupling. It is also the target for
hundreds of disease mutations that cause malignant hyperthermia (MH) or
skeletal muscle disorders like central core disease (CCD). MH is typically
triggered by volatile anesthetics, but their binding site on RyR1 has not
been fully described. RyR1 is under the control of several auxiliary proteins.
One of these is Calmodulin (CaM), a Ca2þ-binding protein that can suppress
RyR1 activity at elevated Ca2þ concentrations. Here we investigate how
CaM can bind to RyR1, and how this may be affected by volatile anesthetics.
We found that CaM can bind to at least three different RyR1 peptides, with
the affinity and lobe specificity being altered substantially by the Ca2þ
concentrations. In addition, we identified two binding sites for sevoflurane,
a volatile anesthetic, on Ca2þ/CaM. The anesthetic binds to a pocket that is
involved in binding RyR1 peptides. In addition, it can alter the affinity of
the N-terminal CaM lobe for Ca2þ. These findings suggest that binding of
anesthetics to CaM may be involved in the pathophysiology of malignant
hyperthermia.
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In skeletal muscle, RyR1 (5,037 residues) forms a homo-tetrameric Ca2þ-re-
lease channel in the sarcoplasmic reticulum (SR), mediates excitation-
contraction coupling in response to an orthograde signal from the DHPR in
the plasma membrane, and retrogradely enhances L-type Ca2þ current via
the DHPR. The RyR1 C-terminus forms the Ca2þ channel pore across the
SR membrane and is believed to be important for inter-subunit interactions,
whereas the bulk (~85%) of the protein (the so-called foot) bridges the junc-
tional, myoplasmic gap between the SR and plasma membranes. Here, we
have examined the ability of the foot domain (residues 1-4300; RyR11:4300)
to target junctionally and interact with the DHPR by expression of a cDNA en-
coding YFP-RyR11:4300. In dysgenic (a1S-null) myotubes which lack DHPRs,
YFP-RyR11:4300 was diffusely distributed and, on the basis of photobleaching,
freely mobile within the cytoplasm, consistent with the loss of membrane an-
choring. However, after expression in dyspedic (RyR1 null) myotubes (which
have DHPRs), much of YFP-RyR11:4300 was immobile within fluorescent foci
near the myotube surface, suggestive of junctional targeting and binding to
DHPRs. Junctional targeting was confirmed by partial co-localization of
YFP-RyR11:4300 and CFP-labeled a1S after co-expression in dyspedic myo-
tubes. Strikingly, YFP-RyR11:4300 was able to retrogradely enhance peak
Ca2þ current in dyspedic myotubes from 1.6 pA/pF (control) to 6.7 pA/pF, sim-
ilar to that after expression of full-length RyR1 (7.4 pA/pF). Thus, the isolated,
cytoplasmic foot of RyR1 retains the ability to target junctionally and to inter-
act functionally with the DHPR.
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In skeletal muscle, the dihydropyridine receptor (DHPR) in the plasma mem-
brane engages in bi-directional interactions with the type 1 ryanodine receptor
(RyR1) in the sarcoplasmic reticulum (SR) such that an ‘‘orthograde’’ signal
from the DHPR triggers SR Ca2þ release via RyR1, and a retrograde signal
